UBS AM’s Antares Pharma, Inc. ATRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-173,438
Closed -$711K 2830
2022
Q1
$711K Buy
173,438
+2,283
+1% +$8.28K ﹤0.01% 2306
2021
Q4
$611K Buy
171,155
+3,555
+2% +$12.4K ﹤0.01% 2469
2021
Q3
$610K Buy
167,600
+1,730
+1% +$7K ﹤0.01% 2415
2021
Q2
$723K Buy
165,870
+918
+0.6% +$3.74K ﹤0.01% 2380
2021
Q1
$678K Buy
164,952
+8,800
+6% +$38.1K ﹤0.01% 2271
2020
Q4
$623K Hold
156,152
﹤0.01% 2213
2020
Q3
$422K Hold
156,152
﹤0.01% 2205
2020
Q2
$429K Sell
156,152
-15,267
-9% -$42.6K ﹤0.01% 2179
2020
Q1
$405K Buy
171,419
+10,203
+6% +$34.7K ﹤0.01% 2057
2019
Q4
$758K Buy
161,216
+56,451
+54% +$231K ﹤0.01% 2055
2019
Q3
$350K Buy
104,765
+54,681
+109% +$180K ﹤0.01% 2403
2019
Q2
$165K Hold
50,084
﹤0.01% 2581
2019
Q1
$152K Buy
50,084
+4,900
+11% +$15.9K ﹤0.01% 2525
2018
Q4
$123K Buy
+45,184
New +$149K ﹤0.01% 2495
2015
Q4
Sell
-63,096
Closed -$107K 2724
2015
Q3
$107K Hold
63,096
﹤0.01% 2605
2015
Q2
$131K Buy
63,096
+3,500
+6% +$8.49K ﹤0.01% 2650
2015
Q1
$162K Buy
59,596
+3,700
+7% +$9.39K ﹤0.01% 2527
2014
Q4
$144K Hold
55,896
﹤0.01% 2535
2014
Q3
$102K Sell
55,896
-965,400
-95% -$2.1M ﹤0.01% 2511
2014
Q2
$2.73M Sell
1,021,296
-106,300
-9% -$320K ﹤0.01% 1207
2014
Q1
$3.95M Buy
1,127,596
+253,300
+29% +$1.12M ﹤0.01% 1100
2013
Q4
$3.92M Sell
874,296
-42,000
-5% -$171K ﹤0.01% 1066
2013
Q3
$3.72M Buy
916,296
+30,100
+3% +$131K ﹤0.01% 1053
2013
Q2
$3.69M Buy
+886,196
New +$3.42M ﹤0.01% 1034

Other funds holding ATRS

UBS AM's ATRS Position: Q2 2022 in Review

UBS AM sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 173,438 shares — an estimated $711K sold.

UBS AM first reported a position in ATRS in Q2 2013 and held it in 24 quarters. The position peaked at $3.95M in Q1 2014. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.

  • UBS AM reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
  • UBS AM sold 173,438 Antares Pharma, Inc. shares in Q2 2022, an estimated $711K.
  • UBS AM first reported a position in Antares Pharma, Inc. in Q2 2013 and held it in 24 quarters.
  • UBS AM's Antares Pharma, Inc. position peaked at $3.95M in Q1 2014.
  • 1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.

Based on UBS AM's 13F filing for Q2 2022, filed 12 Aug 2022.